Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Zenas, a China-US Startup, Breaks Cover with Seven Autoimmune Candidates

publication date: Mar 23, 2021

Zenas BioPharma, a cross-border startup, has in-licensed a portfolio of seven candidates for autoimmune and rare diseases.  Zenas, with operations in Hong Kong and Boston, owns worldwide rights to three of its seven pipeline programs. The company claims its expertise in autoimmune diseases helps it to select candidates with best-in-class potential. It plans to use development and commercial strategies to meet patient needs and the requirement for value. Zenas was founded by Tellus BioVentures and Fairmount Funds Management. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital